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Background: The Psoriasis Disability Index (PDI) is a widely used instrument to measure the impact of psoriasis on
patients. There has not been psychometric evaluation of the Chinese version of PDI. The aim of this study was to
evaluate its reliability and validity among Chinese patients with psoriasis.
Methods: A multi-center, cross-sectional study was conducted at 9 hospitals including patients aged 18 years and
over. Reliability was determined by internal consistency using Cronbach’s alpha. Validity was assessed through
convergent validity and known groups validity. Dimensionality of the PDI was examined by exploratory factor
analysis in working patients and nonworking patients respectively.
Results: In all, 831 patients were studied. Internal consistency of the PDI was satisfactory. Cronbach’s alpha
coefficient was 0.91 for the total score and over 0.70 for each subscale of the PDI. Evidence of convergent validity of
the PDI was proved by excellent and moderate to good correlations with the Dermatology Life Quality Index (DLQI)
and four subscales of the Short Form-36 (SF-36) (role-physical, bodily pain, social functioning, and role-emotional):
r= 0.51-0.78. Known groups validity was confirmed that the PDI score discriminated well among patients with
different severity of psoriasis. The dimensionality of the PDI was determined by the presence of two-factor structure
for working patients and three-factor structure for nonworking patients which accounted for 57.3% and 62.3% of
the variance respectively.
Conclusion: The Chinese version of the PDI is a reliable and valid instrument to assess the impact of psoriasis on
patients’ lives and could be used in future quality of life assessment of Chinese patients with psoriasis.
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Psoriasis is a chronic, systemic, and incurable skin condi-
tion characterized by the skin signs of thick scaling red
plaques with itching and arthritis. It has been proved
that psoriasis is associated with risk of cardiovascular
disease, diabetes, overweight/obesity and depression [1-
5]. Psoriasis can has profound effects on patients’ daily
living and functioning [6-8]. While measurements of
clinical severity separately using tools such as the Psoria-
sis Area and Severity Index (PASI) [9] are not sufficient* Correspondence: fangjq@mail.sysu.edu.cn
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reproduction in any medium, provided the orand may not reflect patients’ own perceptions of the im-
pairment due to psoriasis, it is important to assess the
impact of psoriasis on patients’ physical condition, self-
perception, and social life [10,11]. Health-Related Quality
of Life (HRQOL), covering almost all these parameters,
is therefore increasingly part of the clinical research and
practice. HRQOL assessment can provide valuable infor-
mation that helps make clinical decision and select suit-
able health care programmes [12,13].
There has been a wide variety of generic, dermatology
and psoriasis-specific instruments used for the assess-
ment of HRQOL of psoriasis patients [14-18]. However,
the reliability and validity of these instruments are not
fully known [19-21]. The reliability and validity are theThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ing concepts or ideas such quality of life (QOL) in a
study population [22]. Evaluating the characteristics of
instruments used to measure patients’ perceptions is im-
portant in clinical health care and decision making.
The Psoriasis Disability Index (PDI) [15], as a psoriasis-
specific instrument, was one of the attempts to measure
and quantify the impact of psoriasis on patients’ daily lives
. It has been used internationally for almost 20 years and
has been translated into at least 13 languages [23]. The re-
liability and validity of the PDI have been evaluated using
different languages and in different psoriasis populations.
However, the Chinese version of PDI has not been for-
mally validated in Chinese patients with psoriasis. In
China, HRQOL research has made a remarkable progress
in patient populations [24], but studies on patients with
psoriasis at a population level are limited. One of the main
reasons is a lack of suitable instruments in Chinese.
In this study, permission was sought and thereby given
from the developers of the PDI. Then we used psycho-
metric methods to evaluate the reliability and validity of
the Chinese version of PDI in patients with psoriasis.
Materials and methods
Study design and subjects
A multi-center, cross-sectional study of patients with
psoriasis in 9 large hospitals was performed from No-
vember 2010 to April 2011. For a representative sample
of Chinese patients with psoriasis, outpatients and inpa-
tients with psoriasis were recruited consecutively in der-
matological clinics of the 9 hospitals located in different
geographical regions of China. In the north and south of
China, respectively two hospitals participated in the
study. In the east and middle of China, respectively one
hospital participated in the study. In the west of China,
three hospitals participated in the study. Inclusion cri-
teria for this study were: (1) a clinical confirmed psoriasis
diagnosis; (2) age 18 years or older; and (3) willingness
to provide consent to participate. Patients were excluded
if they had a severe mental illness.
After the purpose and the contents of the study had
been fully explained to the subjects, written informed
consent was obtained. Then all participants were asked
to fill out the questionnaires according to their own feel-
ings and opinions. Those who have difficulties in com-
pleting questionnaires by themselves finished the
questionnaires with the help of trained investigators,
who have been trained that every answer should be
solely based on participant’s own response. Completed
questionnaires were collected as soon as they were
finished.
This study was approved by the Ethics Committee of
the Guangdong Provincial Hospital of Traditional Chin-
ese Medicine.Measurement tools
The measurement tools consisted of PDI, Dermatology
Life Quality Index (DLQI), Health Survey Short Form
(SF-36) and PASI. The DLQI and SF-36 were used to
evaluate the convergent validity of the PDI. The PASI,
frequently as an assessment of the severity of psoriasis,
was used to evaluate the known groups validity of the
PDI.
Psoriasis disability index (PDI)
The PDI, developed by Finlay and Coles, concerns the
functional lifestyle disabilities caused by psoriasis [15]. It
contains 15 items with 5 subscales: daily activities, work,
personal relations, leisure, and treatment. All items are
rated on a 4-point scale, with responses of “not at all”, “a
little”, “a lot”, and “very much” scored 0, 1, 2, and 3, re-
spectively. Item scores are summed to yield a total score
(range: 0–45) with higher score indicating greater limita-
tions experienced because of psoriasis. Particularly, the
PDI has a possible 5 work items of which only 3 items
need to be responded. Respondents who are working (ei-
ther full- or part-time) respond to item 6a, 7a, and 8,
whereas respondents who are not working respond to
items 6b, 7b, and 8. When one item of the PDI was not
responded, it was scored “0”. When two or more items
of the PDI were not responded, the questionnaire was
excluded from the analysis.
Dermatology life quality index (DLQI)
The DLQI, developed by Finlay and Khan, assesses the
QOL impact of skin disease [14]. Comprising 10 items,
the DLQI has been used internationally for more than
15 years and translated into more than 80 international
languages [25,26]. Each item is scored on a 4-point scale
(range 0–3). The final score on the questionnaire is the
sum of the score of each item (range 0–30). Higher
scores indicate worse QOL. Its Chinese version has been
evaluated and shown good psychometric properties [27].
Short form-36 (SF-36)
The SF-36 is a measure of health status and is commonly
used in clinical and health services research [28]. Its
Chinese version has been tested for psychometric prop-
erties [29]. It consists of 8 subscales: physical function
(PF), role-physical (RP), body pain (BP), general health
(GH), vitality (VT), social functioning (SF), role-emo-
tional (RE), and mental health (MH). The scores of the 8
subscales are calculated according to the scoring algo-
rithm of the SF-36 user’s manual. The higher score, the
better health. .
Psoriasis area and severity index (PASI)
The PASI assessed both intensity and extent of the psori-
atic plaques separately for four anatomical regions (head,
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The PASI score ranges from 0 (no psoriasis) to 72 (very
severe psoriasis), and it was normally regrouped into
three categories implying three severity levels of psoria-
sis: PASI 0–7 (mild severity), PASI 7–12 (moderate se-
verity), and PASI 12–72 (severe severity) [30].
Furthermore, demographic and psoriasis-specific vari-
ables such as age, gender, marital status, education, co-
existing chronic disease, family history of psoriasis, dur-
ation, and clinical type of psoriasis, were reported.
Statistical analysis
For each subscale of the PDI, the floor and ceiling effects
were assessed. If more than 20% of the patients reported
lowest or highest possible score, the floor or ceiling
effects exist [31]. Cronbach’s alpha and item-total corre-
lations were determined to assess the internal
consistency. Construct validity, which hypothesizes a
scale measure or correlate with the theorized psycho-
logical scientific construct that it purports to measure,
was assessed by convergent validity and known groups
validity. Convergent validity assessed the degree to which









18-30 years 65(37.8) 61(33.9)
31-45 years 49(28.5) 64(35.6)
46-60 years 44(25.6) 39(21.7)
60 years 14(8.1) 16(8.9)
Marital status (%)




Level of education (%)
None 0(0.0) 3(1.7)
Primary school 8(4.6) 13(7.2)
Secondary school 75(43.6) 85(47.2)
College 83(48.3) 72(40.0)
Higher than college 6(3.5) 7(3.9)
Other chronic disease (%) 26.2 31.7
Family history of psoriasis (%) 25.0 22.2
Duration in years mean (SD) 10.3(11.0) 8.0(7.0)
PASI score mean (SD) 11.0(9.5) 11.0(10.2)that it should theoretically be associated to. Spearman’s
rank correlation coefficient was used to assess correla-
tions between the PDI and the DLQI, the SF-36, which
are the two potential measures that assess similar under-
lying phenomenon as the PDI. Known groups validity
tested the ability of the PDI to discriminate between
groups that differed in the severity of psoriasis (assessed
by PASI). The Kruskal-Wallis test was used to test for
statistical differences between the groups. Dimensionality
of the PDI was analyzed for patients who were working
and not working separately because the work items of
the PDI were different for working and nonworking
patients. Exploratory factor analysis was used by means
of principal component analyses. Oblique rotation (pro-
max) was performed according to the supposed correla-
tions between the factors.
All statistical analysis was performed using SPSS 17.0
(SPSS Inc., Chicago, IL, USA).
Results
Subjects
In total, 884 patients participated in this study. Out of










55(57.3) 164(57.7) 74(74.7) 513(61.7)
41(42.7) 120(42.3) 25(25.3) 318(38.3)
25(26.0) 113(39.8) 24(24.2) 288(34.7)
31(32.3) 117(41.2) 46(46.5) 307(36.9)
25(26.0) 35(12.3) 23(23.2) 166(20.0)
15(15.6) 19(6.7) 6(6.1) 70(8.4)
70(72.9) 196(69.0) 76(76.8) 579(69.7)
22(22.9) 84(29.6) 22(22.2) 233(28.0)
4(4.2) 3(1.1) 1(1.0) 13(1.6)
0(0.0) 1(0.4) 0(0.0) 6(0.7)
1(1.0) 0(0.0) 1(1.0) 5(0.6)
1(1.0) 30(10.6) 3(3.0) 55(6.6)
40(41.7) 109(38.4) 36(36.4) 345(41.5)
52(54.2) 139(48.9) 56(56.6) 402(48.4)
2(2.1) 6(2.1) 3(3.0) 24(2.9)
26.0 29.2 19.2 27.6
26.0 19.0 26.3 22.6
11.0(10.0) 8.4(8.8) 11.3(7.1) 9.3(9.0)
9.8(8.6) 12.0(11.8) 14.0(10.6) 11.6(10.6)
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missing answers on the PDI. Hence, the analysis was car-
ried out on a total of 831 patients (94%).
At study inclusion the mean age of patients was
38.6 years (SD = 13.8) and a higher proportion of
patients were males than females (62% vs.38%).
cardiovascular, musculoskeletal, gastrointestinal, ana-
phylactic, and gynecological diseases. Twenty-three per-
cent of patients had a family history of psoriasis. The
mean duration of psoriasis was 9.3 years (SD = 9.0). The
most common clinical type of psoriasis was psoriasis vul-
garis (92%), followed by erythrodermic psoriasis (4%),
psoriatic arthritis (3%), and pustular psoriasis (1%). The
mean severity of psoriasis assessed by PASI was 11.6 (SD
= 10.6). Further demographic and clinical characteristics
of the patients from different geographical regions are
shown in Table 1.
Response distribution
All subscales of the PDI had small ceiling effects (<6%)
but mild floor effects (>20%) for work, personal, and
treatment (Table 2).
Reliability
The means, standard deviations, percentiles, corrected
item-total correlations, and Cronbach’s alpha coefficients
of the PDI and its subscales are presented in Table 2.
The subscales of PDI showed Cronbach’s alpha coeffi-
cients above 0.7, and the item-total correlation ranged
from 0.32 to 0.74, which suggested an adequate internal
consistency of the PDI [32,33].
Convergent validity
Convergent validity was assessed as satisfactory. The cor-
relations between the total PDI score and the DLQI, SF-
36 are shown in Table 3. Correlations from 0.25 to 0.50






Daily activities 5(0–15) 5.3 3.5 3 5 8
Work 3(0–9) 2.5 2.5 0 2 4
Personal 2(0–6) 1.3 1.6 0 1 2
Leisure 4(0–12) 2.9 2.6 1 2 4
Treatment 1(0–3) 0.7 0.9 0 1 1
Total 15(0–45) 12.8 9.4 6 11 18
English version b
Total score 15(0–45) 7.3 7.2 2 - 11
a Scale consists of one item.
b From a validation study done in the United States [32].are moderate to good; and values greater than 0.75 are
considered good to excellent [34]. Results in Table 3
showed excellent correlation between the PDI and the
DLQI, moderate to good correlations between the PDI
and four subscales of the SF-36 (RP, BP, SF, and RE), and
fair correlations between the PDI and the other subscales
of the SF-36. There were negative correlation coefficients
between the PDI and SF-36 score, because higher PDI
score indicated greater functional lifestyle disabilities,
whereas higher SF-36 score indicated better health or
performance.Known groups validity
According to the PASI score assessed by physicians,
there were 348 patients (42%) with PASI <7, 195
patients (23%) with PASI 7–12, and 288 patients (35%)
with PASI ≥ 12. Therefore, the subjects were divided into
three “severity” groups: mild, moderate, and severe. The
PDI score showed significantly different among the three
groups (Kruskal-Wallis testχ2=76.30, P< 0.001) and
increased with the increasing severity of psoriasis
(Figure 1).Dimensionality of the PDI
Exploratory factor analysis using an eigenvalue of >1.0
as the criterion resulted in two factors for working and
three for nonworking subjects (Table 4), which
accounted for 57.3% and 62.3% of the total PDI variance,
respectively. All the 15 items were retained when the cri-
terion of highest loading was used, above 0.40 and at
least 0.10 stronger than the next. For working subjects,
the first factor may reflect working and social disabilities
and the second factor may reflect hygienic disability. For
nonworking subjects, the first two factors contained the
same items as those for the working subjects but item 14
(More smoke/drink), which was extracted separately as
the third factor.PDI total scale and its subscales
% floor % ceiling Corrected item-total
correlation
Cronbach's α
5.2 1.7 0.58-0.70 0.82
27.9 4.5 0.62-0.72 0.86
30.4 4 0.64-0.65 0.79
17.9 0.8 0.32-0.65 0.74
34.7 5.7 -a -a
3.1 0.5 0.37-0.74 0.91
14.7 0 - -
Table 3 Spearman’s rank correlation coefficients between
the total PDI score and the DLQI, SF-36 scores
N rs(P)
DLQI 815 0.78 a (<0.001)
SF-36
Physical functioning 800 −0.42 c (<0.001)
Role-physical 818 −0.58 b (<0.001)
Bodily pain 822 −0.51 b (<0.001)
General health 803 −0.34 c (<0.001)
Vitality 809 −0.40 c (<0.001)
Social functioning 814 −0.65 b (<0.001)
Role-emotional 826 −0.58 b (<0.001)
Mental health 796 −0.45 c (<0.001)
a Excellent correlation. b Moderate to good correlation. c Fair correlation.
N: Sample size when correlation was calculated. rs: Spearman’s rank correlation
coefficients.
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As it is increasingly important to assess the impact of
psoriasis on the lives of patients, this study adapted an
original English and widely used scale PDI to Chinese
psoriasis patients. The Chinese version of the PDI was
proved to have good reliability and validity by the data
presented here.Response distribution of the PDI
A moderate percentage of patients were likely to re-
sponse “Not at all” affected by psoriasis for the work,
personal, and treatment subscales of the PDI. ComparingFigure 1 Box plot of the PDI score stratified to severity of psoriasis asto the large floor effects conducted in a US study (>49%
except daily activities), the floor effects of the Chinese
version of PDI were smaller while both ceiling effects
were small [32]. The mild floor effects might suggest that
some items of the PDI provide limited information on
the disabilities caused by psoriasis, especially for those
with low level of disabilities and severities.
Reliability and validity of the PDI
The internal reliability estimated by Cronbach’s alpha
exceeded 0.7 in the total scale and all subscales of the
PDI, which indicated a good reliability of the instrument.
Similar results have been found in other language ver-
sions of the PDI [32,35,36]. Regarding the validity, excel-
lent and moderate to good correlations with the DLQI
and certain subscales of the SF-36 added to available evi-
dence of convergent validity for the PDI. The English
and Norwegian versions of the PDI have also proved
their convergent validity [32,35]. The results of known
groups comparison indicated the discriminate ability of
the PDI was good enough to distinguish the patients
with different severities of psoriasis, which was consist-
ent with previous studies [32].
Dimensionality of the PDI
The items of PDI were grouped into five subscales based
on common sense when the PDI was developed [15].
However, the original structure could not be confirmed
by factor analysis [37], and no consensus exists regarding
the number of factors composing this scale. It has beensessed by the PASI.
Table 4 Exploratory factor analysis of the PDI
Scales Items











Dailyactivities 1. House/garden work .46 .33 .51 .34 .03
2. Different clothes -.03 .80 .17 .63 -.06
3. Change/wash clothes .02 .81 .04 .85 -.05
4. Hairdresser problem -.05 .79 .32 .49 .01
5. More baths -.11 .82 -.30 .96 .07
Work 6a. Time off work .83 -.02 - - -
7a. Inhibit work .81 -.01 - - -
6b. Less activity - - .83 .03 -.05
7b. Different activity - - .70 .18 -.10
8. Career affected .86 -.09 .80 -.21 .04
Personalrelations 9. Sexual difficulties .75 .00 .87 -.11 -.06
10. Social relations .73 .07 .81 -.01 .00
Leisure 11. Social activities .61 .23 .69 .15 .01
12. Sport difficulties .55 .25 .85 -.07 -.05
13. Communal changing .77 -.11 .51 .01 .41
14. More smoke/drink .62 -.13 -.06 -.00 .96
Treatment 15. Home messy/untidy .60 .22 .52 .14 .12
Bold values indicate the largest factor loadings for each item.
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hygienic disabilities respectively could underlie the dis-
abilities construct in the Norwegian version [35]. Our
results confirmed the two factors conception of the PDI
for the working patients, one concerning work-related
disabilities, the other concerning hygiene and embarrass-
ment, which was consistent with the results obtained in
a US sample [32]. For nonworking patients, our results
indicated a similar factor structure as those for working
patients, which was not consistent with the extraction of
one-factor structure in the US sample, however [32]. The
differences between present results and the results in the
US sample might be partly due to differences in sample
characteristics. The multidimensionality of the PDI
documented by the existing studies could compromise
the validity of the total score of PDI when it is used for
measurement of impact of psoriasis.
Strengths and limitations
This study is important as being the first study to evaluate
reliability and validity of the Chinese version of PDI based
on a relatively large sample of Chinese patients with psoria-
sis. The results presented here provide reasonable evidence
to show that the Chinese version of PDI has good reliability
and validity. There are some limitations, however. Because
the PDI was administrated once to the subjects, test-retest
reliability, responsiveness to change, and minimal clinical
important difference (MCID) were not evaluated. The dif-
ferential item functioning (DIF) among patients withdifferent demographic variables and cultural background
was not evaluated. Enrolled in large hospitals only, the
study sample can not be regarded as representative of all
Chinese patients with psoriasis. Moreover, there were
nearly 30% sample subjects suffering other chronic disease.
The reliability and validity of the PDI in these patients need
further studies.
Conclusion
The Chinese version of PDI is a reliable and valid instru-
ment and can be used to assess patient-reported impact
of psoriasis. It is expected to help improve the QOL as-
sessment of Chinese patients with psoriasis because until
now there have been few instruments to measure psoria-
sis-specific QOL in China. The results are comparable to
those of the original English version and translated ver-
sions in other countries. Therefore, international co-
operative research could use the scale to measure QOL
in patients with psoriasis.
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